Introduction: Although gastrointestinal hemorrhage is an important complication for dialysis patients, the details of many points remain unclear with regard to small intestinal lesions.
INTRODUCTION
The frequency of gastrointestinal hemorrhage is high in dialysis patients. 1 Fecal occult blood tests are performed to discover lesions. We often encounter patients in whom no hemorrhagic lesion is identified in the stomach, duodenum, or large intestine even though the fecal occult blood test is positive.
Small intestinal lesions are classified into erosive and vascular lesions based on endoscopic findings. Many reports have been published on the frequent use of non-steroidal anti-inflammatory drugs (NASIDs) as a cause of the lesions. 2 A relationship between Proton pump inhibitor (PPI) and small intestinal lesions has been recently reported. 3 In this study, we used capsule endoscopy to observe small intestinal lesions in patients who did not show hemorrhagic lesions in previous gastroscopic or colonoscopic examinations despite being fecal occult bloodpositive.
METHODS
Patients with two consecutive fecal occult blood tests performed within a month of each other and no hemorrhagic lesions noted on gastroscopy and colonoscopy were eligible to participate in the study.
For the fecal occult blood test, the latex test was used. The test was performed twice per month, and gastroscopy and colonoscopy procedures were performed for patients who were positive for both tests. The endoscopy procedures were performed by multiple endoscopists who each had more than 10 years' experience. For patients with no hemorrhagic lesion in the stomach, duodenum, or large intestine, capsule endoscopy was performed.
The patients fasted from 21:00 on the day before capsule endoscopy, and ingested 24 mg of Sennoside before sleep and Niflec ® on the morning of the test day. They ingested a capsule endoscope at 9:00 AM, and its excretion in the evening of the same day was confirmed. For the capsule endoscope, PillCam ® SB (Givenimaging Ltd.) was used. The dialysis patients underwent capsule endoscopy on non-dialysis days. The same two gastrointestinal physicians read the images of the small intestine for diagnosis.
Data are expressed as the mean AE SD, or median (interquartile range) for normal and non-normal continuous variables, respectively. For between-group analyses of demographic factors and clinical values, Fisher's exact test was performed. Relative risks of erosion or vascular lesions between dialysis patients and non-dialysis patients were also calculated.Two-sided P values less than 0.05 were considered significant. Statistical analyses were performed using Stata version 11.2 (Stata Corp., College Station, TX, USA) and JMP (version 8.0.2; SAS Institute, Cary, NC, USA).
The protocol of this study was approved by the Human Ethics committee of Moriguchi Keijinkai Hospital. Informed consent was obtained from all patients prior to participation.
RESULTS
The mean age was 71.2 AE 12.1 years (mean AE SD) old in the dialysis group (n = 16) and 68.5 AE 15.2 years old (mean AE SD) in the non-dialysis group (n = 20). The mean duration of dialysis was 88.8 AE 67.2 months (mean AE SD) in the dialysis group (Table 1) .
Regarding oral medication related to small intestinal hemorrhage, antiplatelet drugs were administered to 62.5% (10/16) and 25.0% (5/20) in the dialysis and non-dialysis groups, respectively. The antiplatelet drug was Aspirin or Clopidogrel Sulfate. PPI were administered to 93.7% (15/16) and 15.0% (3/20), respectively. PPI was Lansoprazole or Rabeprazole and NSAIDs were administered to 31.2% (5/16) and 15.0% (3/20), respectively. NSAID was Loxoprofen sodium hydrate in all cases (Table 1) .
Capsule endoscopy was safely performed without any complications in all patients.
Vascular lesions were observed in 10 of the 16 dialysis patients and 5 of the 20 non-dialysis patients, and erosive ulcerative lesions were observed in 8 and 5, respectively ( Figure 1 ). Vascular lesions were observed at a significantly higher rate in the dialysis patients (P = 0.041), but no significant difference was noted in the erosive lesion detection rate (P = 0.188; Tables 2 and 3). Data are mean AE SD or number of patients. Anti-PLT = anti-platelet drugs; NSAIDs = non-steroidal anti-inflammatory drugs; PPI = proton pump inhibitor. Regarding the relationship between the oral drugs and small intestinal lesions, vascular lesions were significantly more common in patients receiving PPI (P = 0.02).
However, antiplatelet drugs and NSAIDs showed no relationship. The vascular lesions were not related to the dialysis duration (P = 0.39; Table 1 ).
No particular treatment of small intestinal lesions was performed after examination. Anemia did not progress. Subjective symptoms did not developed in any patient.
DISCUSSION
The gastrointestinal hemorrhage complication rate is high in dialysis patients. 1 Gastrointestinal hemorrhage has a high risk of repeat episodes and can increase the risk of death. 4 Reportedly, a high frequency of hemorrhage from not only gastric ulcer and a diverticulum of the large intestine but also vascular lesions, such as angiodysplasia, is characteristic of dialysis patients. 5 Accordingly, the early discovery of gastrointestinal hemorrhage is important.
Fecal occult blood tests include latex, orthotolidine, and guaiac tests, but orthotolidine and guaiac tests are influenced by the ingestion of meat. Since the latex test used in this study is an immunological test specifically reacting with hemoglobin, it is unlikely to be influenced by food and its sensitivity is high. 6 Based on these factors, we adopted the latex test.
The combination of several methods is useful to examine the digestive tract in dialysis patients. 7, 8 Previously, the endoscopic diagnosis and treatment of small intestinal hemorrhage was difficult, and the only method available was angiography. 9 Widespread use of double balloon and capsule endoscopic procedures are diagnosing more small intestinal disease. Capsule endoscopy, introduced to Japan in 2007, has recently been used to diagnose lesions in the esophagus and large intestine in addition to the small intestine. 10 Only a few cases of capsule endoscopy in dialysis patients have been reported. Ohmori et al. performed capsule endoscopy in 13 dialysis patients, and observed erosive ulcerative lesions in 30.7% and vascular lesions in 61.5%. 7 We examined fecal occult blood-positive patients, while Ohmori et al. included only anemia patients. Despite of this difference, both studies demonstrated that vascular lesions were a more frequent complication than erosive lesions and that the rate of complicating vascular lesions was about 60%. Although both vascular and erosive lesions were observed in 5 of 16 dialysis patients and in 3 of 20 non-dialysis patients, no common cause could be identified in this study.
The cause of ulcerative small intestinal lesions may be NSAIDs, anticoagulants including low-dose aspirin, or an increase in infectious small intestinal disease. 11, 12 NSAIDs damage the small intestinal mucosa at a high rate, 13 but no significant difference was noted in our findings.
According to Kuroda et al. 14 and Pozzoli et al., 15 PPI exhibit a preventive effect against indomethacin-induced small intestinal injury, and the anti-inflammatory effect and antioxidative action of PPI are considered as possible action mechanisms. However, the main action of PPI is the inhibition of gastric acid secretion, and they may be administered for a prolonged period to prevent GERDand NSAID-induced gastric and duodenal lesions, for which a negative influence of the long-term inhibition of gastric acid secretion on the small intestine is of concern. 15 Washio et al. reported that the combined use of PPI and NSAIDs caused more small intestinal injuries than NSAIDs alone. 16 PPIs were considered as a cause for small intestinal lesions. When no hemorrhagic lesion is observed in the upper digestive tract or large intestine despite being fecal occult blood-positive, small intestinal lesions should be taken into consideration. The frequent use of PPI may induce small intestinal diseases.
Further studies on small intestinal lesions in dialysis patients are expected.
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